Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000431349 | SCV000530121 | uncertain significance | not provided | 2024-07-12 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV002059821 | SCV002402156 | likely benign | Kufor-Rakeb syndrome; Autosomal recessive spastic paraplegia type 78 | 2024-04-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002418306 | SCV002722906 | uncertain significance | Inborn genetic diseases | 2018-03-29 | criteria provided, single submitter | clinical testing | The p.R66H variant (also known as c.197G>A), located in coding exon 3 of the ATP13A2 gene, results from a G to A substitution at nucleotide position 197. The arginine at codon 66 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species, and histidine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |